by Janncike Kristoffersen | Dec 2, 2025
Inven2 has launched Inven2 Marketplace – a new digital platform that consolidates all our available technologies and licensing opportunities in one place. Throughout November, Inven2 has gradually rolled out its new marketing platform, Inven2 Marketplace, which is now...
by Janncike Kristoffersen | Sep 16, 2025
After six intensive months of development, mentoring, and investor preparation, Norway’s first national biotechnology accelerator program, The Forge, concluded with an exciting pitch competition. Here, participants were given the opportunity to present their...
by Janncike Kristoffersen | Mar 1, 2025
Inven2 is now collecting ideas for this year’s idea competition. The winner will receive 300.000 kroner, in addition to advice and assistance in taking the idea further into the market. The submission deadline is May 1st 2025. “The Innovation Award”...
by Janncike Kristoffersen | Jan 21, 2025
The Clinical Research Unit at Oslo University Hospital was selected as the sole centre worldwide to conduct a “first-in-human” study of an entirely new MRI contrast agent. Much of the preclinical development were carried out in Norway by GE HealthCare...
by Janncike Kristoffersen | Jan 6, 2025
2024 ended on a positive note. Zelluna and Ultimovacs merged in an exciting collaboration to advance their precision cell therapies into clinical trials. This merger was strengthened by over NOK 50 million in fresh capital from private investors, including Inven2....
by Janncike Kristoffersen | Oct 21, 2024
Researchers and clinicians at Haukeland University Hospital, the University of Bergen, and the University of Oslo have developed a new method to predict mood-states change in people with bipolar disorder using artificial intelligence. A patent application for the...
